The Soluble Guanylate Cyclase Stimulator IWP-953 Increases Conventional Outflow Facility in Mouse Eyes

Pei Ge, Iris D. Navarro, Marco M. Kessler, Sylvie G. Bernier, Nicholas R. Perl, Renee Sarno, Jaime Masferrer, Gerhard Hannig, and W. Daniel Stamer

1Ironwood Pharmaceuticals, Cambridge, Massachusetts, United States
2Ophthalmology Department, Duke University, Durham, North Carolina, United States
3formerly of Ironwood Pharmaceuticals, Cambridge, Massachusetts, United States

Correspondence: W. Daniel Stamer, Duke University, DUMC 3802, Durham, NC 27710, USA; dan.stamer@duke.edu.
Submitted: December 15, 2015
Accepted: February 11, 2016
Citation: Ge P, Navarro ID, Kessler MM, et al. The soluble guanylate cyclase stimulator IWP-953 increases conventional outflow facility in mouse eyes. Invest Ophthalmol Vis Sci. 2016;57:1317–1326. DOI:10.1167/iovs.arvojournals.org

G laucoma is a progressive and degenerative optic neuropathy associated with irreversible loss of vision, starting with peripheral visual field loss and moving centrally. Primary open-angle glaucoma (POAG) is the most common form resulting in chronic degeneration of retinal ganglion cell axons at the level of the lamina cribrosa and subsequent apoptotic cell death.1 Chronically elevated intraocular pressure (IOP) is the major modifiable risk factor, with several prospective, randomized multicenter studies showing that effective IOP lowering decreases structural and functional damage to optic nerve axons.2

Intraocular pressure is generated and maintained via the conventional (trabecular) outflow pathway, a pressure-driven system, is responsible for generation and maintenance of IOP under physiological conditions and provides resistance to unobstructed AH outflow.3,4

At present, the only proven treatment in the management of glaucoma is directed toward lowering IOP either by increasing the rate of conventional outflow or reducing AH production. Among the five classes of drugs most commonly used, two of them, prostaglandin analogs and cholinergics, lower IOP by primarily affecting outflow. Prostaglandins increase the outflow of AH through the secondary outflow route, the uveoscleral pathway, and cholinergic agents (generally restricted to acute use) indirectly affect the conventional pathway by contracting the ciliary muscle. The other three classes, carbonic anhydrase inhibitors, adrenergic agonists, and β-blockers, act by decreasing AH production.1 On the horizon, rho-associated kinase (ROCK) inhibitors are in late stage clinical development, emerging as the first pharmacologic class of drugs that decrease IOP by directly increasing conventional outflow. These drugs primarily act by altering the actin cytoskeleton and contractility of trabecular meshwork (TM) cells.5 Additionally, latanoprostene bunod (Vesneo; Baush and Lomb, Rochester, NY, USA), a topically administered nitric oxide (NO)-donating prostaglandin F2-alpha analog, is currently under review by the Food and Drug Administration (FDA) as an IOP-lowering single-agent eye drop. Vesneo is metabolized into the prostaglandin analog latanoprost acid and NO upon instillation in the eye, theoretically targeting both uveoscleral and conventional outflow.

PURPOSE. The nitric oxide (NO)–cyclic guanosine-3′,5′-monophosphate (cGMP) pathway regulates aqueous humor outflow and therefore, intraocular pressure. We investigated the pharmacologic effects of the soluble guanylate cyclase (sGC) stimulator IWP-953 on primary human trabecular meshwork (HTM) cells and conventional outflow facility in mouse eyes.

METHODS. Cyclic GMP levels were determined in vitro in HEK-293 cells and four HTM cell strains (HTM120/HTM123: predominantly myofibroblast-like phenotype, HTM130/HTM141: predominantly endothelial-like phenotype), and in HTM cell culture supernatants. Conventional outflow facility was measured following intracameral injection of IWP-953 or DETA-NO using a computerized pressure-controlled perfusion system in enucleated mouse eyes ex vivo.

RESULTS. IWP-953 markedly stimulated cGMP production in HEK-293 cells in the presence and absence of DETA-NO (half maximal effective concentrations: 17 nM, 9.5 μM). Similarly, IWP-953 stimulated cGMP production in myofibroblast-like HTM120 and HTM123 cells, an effect that was greatly amplified by the presence of DETA-NO. In contrast, IWP-953 stimulation of cGMP production in endothelial-like HTM130 and HTM141 cells was observed, but was markedly less prominent than in HTM120 and HTM123 cells. Notably, cGMP was found in all HTM culture supernatants, following IWP-953/DETA-NO stimulation. In paired enucleated mouse eyes, IWP-953 at 10, 30, 60, and 100 μM concentration-dependently increased outflow facility. This effect (89.5%) was maximal at 100 μM (P = 0.002) and in magnitude comparable to DETA-NO at 100 μM (97.5% increase, P = 0.030).

CONCLUSIONS. These data indicate that IWP-953, via modulation of the sGC-cGMP pathway, increases aqueous outflow facility in mouse eyes, suggesting therapeutic potential for sGC stimulators as novel ocular hypotensive drugs.

Keywords: trabecular meshwork, glaucoma pharmacology, conventional outflow, soluble guanylate cyclase

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Converging evidence implicates the NO-soluble guanylate cyclase-cyclic guanosine-3',5'-monophosphate (NO-sGC-cGMP) signaling pathways in the homeostatic processes involved in conventional outflow resistance regulation and thereby IOP, positioning this pathway as a therapeutic target for pharmacologic intervention in POAG. Studies using pharmacologic NO donors, inhibitors of NO synthases (NOS), inhibitors and activators of sGC, and membrane-permeable analogs of cGMP in vivo in several species, including mouse, dog, rabbit, and monkey, have implicated the NO-sGC-cGMP pathway in the regulation of AHH outflow and IOP. The contribution of NO-sGC-cGMP pathway deficiencies in the development of ocular hypertension and glaucomatous optic neuropathy was revealed further in studies using genetically engineered mice, including sGC-α knockout mice, transgenic mice expressing human endothelial NOS (eNOS), and NOS3 knockout mice. Finally, the identification of a single nucleotide polymorphism risk variant located in the locus encoding the sGCα and sGCβ subunits highlights the potential relevance of sGC in the pathogenesis of POAG. Despite these findings, the precise molecular mechanisms translating NO-sGC-cGMP effects downstream to IOP regulation in the anterior segment of the eye with a secondary effect impacting the optic neuropathy remain to be elucidated.

Soluble guanylate cyclase is the primary NO receptor in mammals and a central component of the NO-sGC-cGMP pathway. This receptor is expressed by two of the contractile cell types (TM and ciliary smooth muscle cells) that modulate conventional outflow resistance. Activation of sGC by NO induces production of cGMP regulating various downstream effector systems including cGMP-dependent protein kinases, ion channels, and phosphodiesterases.

IWP-953 is a novel small molecule sGC stimulator, a member of a class of small molecules that directly bind and activate sGC independently of NO and in synergy with NO.

In this study, we report pharmacologic effects of IWP-953, measured by production of the primary sGC downstream effector, cGMP, in vitro in cellular models, and secondly, investigate whether stimulation of the sGC-cGMP pathway by IWP-953 translates to improved aqueous outflow dynamics in mouse eyes by measuring outflow facility. An ex vivo mouse model was used due to its similarity with regard to the outflow anatomy, physiology, and pharmacologic responses of human eyes.

**Methods**

**Reagents**

Reagents were obtained from the following vendors: DETANoate (DETA-NO; Enzo Life Sciences, Farmingdale, NY, USA), Amersham cGMP Direct Biotrak ELISA (General Electric Healthcare Bio-Sciences, Pittsburgh, PA, USA), 3-isobutyl-1-methylxanthine (IBMX, a phosphodiesterase inhibitor; Sigma-Aldrich Corp., St. Louis, MO, USA), 1-(2,4-dioxazol-5-yl)imidazoline (ODQ; Tocris, Minneapolis, MN, USA). Poly-D-lysine coated flat-bottom plates were obtained from Corning (Kennebunk, ME, USA). IWP-953 is a member of a group of pharmacologic active sGC stimulators developed at Ironwood Pharmaceuticals (Cambridge, MA, USA) by systematic structure-activity exploration around a central pyrazole-pyrimidine motif.

**Cell Culture**

Human embryonic kidney (HEK)-293 cells (CRL-1573) were purchased from ATCC (Manassas, VA, USA) and maintained in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine serum (fBS), 100 U/mL penicillin, and 100 µg/mL streptomycin.

Primary human trabecular meshwork (HTM) cells were isolated and characterized as previously described. For the current project, cells were cultured under conditions to undergo a differentiation step prior to the assay as described below. Four HTM cell strains (HTM120, HTM123, HTM130, and HTM141) isolated from four pairs of human donor eyes (11 months, 39 years, 2 years, and 38 years old) were used in experiments.

**Mouse Eyes**

All experiments were conducted in compliance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and under Institutional Animal Care and Use Committee approval for research at Duke University. Eyes were enucleated from culled C57BL/6 mice procured from several different Duke University laboratories, depending upon availability on the day of experiment.

**Cyclic Guanosine Monophosphate Assays**

Two methods to measure cGMP were used in this study. The amount of cGMP produced in HEK-293 cells was sufficiently high to allow measurement by liquid chromatography-tandem mass spectrometry (LC/MS/MS). In contrast, when lower cGMP levels were expected as in the case of HTM cells, ELISA provided higher sensitivity for measuring cGMP concentrations below the lower level of quantitation for LC/MS/MS.

**HEK-293 Cells**

Human embryonic kidney-293 cells were seeded at a density of 6 × 10⁴ cells/well in 96-well poly-D-lysine coated flat-bottom plates in 50 µL DMEM and incubated 24 hours at 37°C. Culture medium was removed and the cells were washed once with 80 µL Hank’s Balanced Salt Solution (HBSS). Cells were then incubated with 80 µL of a solution containing 0.5 mM IBMX in HBSS for 15 minutes at 37°C. Ten microliters of an ODQ solution (10 µM in HBSS containing 0.5 mM IBMX) or vehicle (0.4% dimethyl sulfoxide) was added to the cells, which were incubated for a further 10 minutes at 37°C. Ten microliters of either IWP-953 (final concentrations: 10⁻¹¹M – 3 × 10⁻⁸M) or vehicle in the presence or absence of DETA-NO (10 µM) was added to the cells, which were further incubated for 20 minutes at 37°C. The selection of this concentration–response curve is based on extensive experience of our laboratory assessing this class of compounds in vitro in potency and other functional assays. Following the incubation step, assay buffer was removed and 50 µL ice cold 10% acetic acid and 150 ng/mL internal standard were added to each well, and samples were incubated on ice for 30 minutes. Following centrifugation (4°C, 5 minutes, 1000g) the amount of cGMP in cell supernatants was determined by LC-MS/MS. Data are expressed as the mean ± standard deviation (SD; N = 2) and are representative of two independent assays.

**HTM Cells**

All HTM cell strains were seeded at the same density, cultured for the same period of time, and cell confluence was monitored by contact inhibition. These culture conditions have repeatedly and consistently produced similar cell numbers for different HTM strains. Briefly, HTM cells were seeded at a density of 1 × 10⁵ cells/well in 24-well plates and
incubated at 37°C in DMEM, containing 10% FBS (Atlanta Biologicals, Flowery Branch, GA, USA). After 1 week, confluent cells were switched to DMEM supplemented with 1.0% FBS for an additional week. The culture medium was then aspirated, the cells washed once with warmed PBS (without calcium and magnesium), and treated with DMEM containing 0.5 mM IBMX for 15 minutes at 37°C. The culture medium was aspirated, and the cells incubated with either vehicle (0.5% DMSO) or IWP-953 (concentration–response curve ranging from 0.01 μM to 10 μM, prepared in 3-fold serial dilution steps in DMEM containing IBMX) in the presence or absence of 10 μM DETA-NO for 15 minutes at 37°C. The incubation was stopped by addition of 500 μl ice cold 0.1 M HCl in distilled H2O, incubated for 30 minutes at 4°C. Cells were scraped from bottom of wells and lysed by repeated up-and-down pipetting. The mixture was centrifuged and the supernatant was transferred to a fresh tube. Both cell lysates and cell culture supernatants were frozen. The concentration of cGMP in HTM cell lysates and HTM culture supernatants was performed using the unpaired (two-tailed) Student’s t-test, compared to control. P < 0.05 is considered statistically significant.

Due to recent findings that pressures greater than 18 mm Hg cause artificial deepening of the anterior chamber (and a subsequent increase in outflow), only data from pressures between 4 to 16 mm Hg were used in the final analysis. A Student’s t-test (paired, two-tailed) was used to compare data sets, using imputed averages for a single data set to replace missing data when one eye of a pair failed to pass the stability criteria. P < 0.05 is considered statistically significant.
RESULTS

IWP-953 Stimulates cGMP Production in HEK-293 Cells

We determined the in vitro pharmacologic potency of IWP-953 in HEK-293 cells, which are known to express high levels of endogenous sGC and to contain high basal cGMP levels. A concentration–response curve ranging from $10^{-11}$ M to $3 \times 10^{-5}$ M was generated for IWP-953 in the presence and absence of the NO donor, DETA-NO (10 μM). As shown in Figure 1, IWP-953 in the presence of DETA-NO (10 μM) potently stimulated the production of cGMP in HEK-293 cells in a concentration-dependent manner, with a calculated half maximal effective concentration (EC₅₀) of 17 nM. The sGC inhibitor, ODQ (10 μM), potently inhibited IWP-953-stimulated cGMP production in the presence of DETA-NO (IWP-953 EC₅₀: 2.2 μM in the presence of ODQ). In the absence of exogenous DETA-NO, IWP-953 stimulated cGMP production but less potent with an EC₅₀: 9.5 μM (Fig. 1), and was further decreased in the presence of ODQ (data not shown).

IWP-953 Stimulates cGMP Production in HTM Cells

The NO–sGC–cGMP signaling pathway is implicated in conventional outflow and thereby, the regulation of IOP. We investigated the in vitro pharmacologic effects of IWP-953 on intracellular cGMP production in four HTM cell strains: two of which (HTM120 and HTM123) have predominantly a myofibroblast-like phenotype, while the other two (HTM130 and HTM141) display an endothelial-like phenotype. A concentration–response curve for IWP-953 (ranging from 0.1–10 μM) was generated to determine effects on cGMP accumulation, either in the presence or absence of DETA-NO (10 μM). In the presence of DETA-NO, IWP-953 elicited significant, concentration-dependent effects on cGMP production in both HTM120 ($P < 0.05$) (Fig. 2A) and HTM123 ($P < 0.05, P < 0.001$) cell strains (Fig. 2B). Concentration-dependent elevations in cGMP levels were also found in HTM130 ($P < 0.01; P < 0.001$) (Fig. 2C) and HTM141 ($P < 0.05, P < 0.01; P < 0.01$; Fig. 2D) cell strains, but these increases were markedly less robust than observed in the other two cell strains (maximal cGMP levels reaching 478 ± 47 and 578 ± 154 pmol/mg protein for HTM130 and HTM141 cultures). In the absence of DETA-NO, cGMP concentrations following IWP-953 stimulation were generally less than 100 pmol/mg protein in all HTM cultures at all concentrations tested (Supplementary Table S1). This reveals a considerably higher magnitude of the synergistic effect of DETA-NO on cGMP production in myofibroblast-like HTM cultures, compared to endothelial-like HTM cultures. Interest-
ingly, the effect of DETA-NO (10 μM, 100 μM) stimulation of cGMP production alone was generally trivial in all HTM cultures (Fig. 2).

IWP-953 Stimulates cGMP Secretion in Supernatants of Human TM Cells

To further investigate whether cGMP produced by HTM cells is secreted, we measured cGMP in cell culture supernatants by ELISA. IWP-953 treatment (0.1–10 μM) in the presence of DETA-NO (10 μM) significantly increased cGMP (*P < 0.05, **P < 0.01, ***P < 0.001) in all HTM culture supernatants (Fig. 3). Interestingly, unlike the measurements of intracellular cGMP, the levels of extracellular cGMP were similar in both the myofibroblast-like and endothelial-like HTM cultures. Maximal levels of cGMP in the supernatants of the myofibroblast-like HTM120 (Fig. 3A) and HTM123 (Fig. 3B) were 59 ± 9 nM and 38 ± 2 nM, respectively. By comparison, maximal levels of cGMP in the supernatants of the endothelial-like HTM130 (Fig. 3C) and HTM141 (Fig. 3D) cell culture supernatants were 15 ± 2 nM and 64 ± 1 nM, respectively. DETA-NO stimulation alone resulted in small amounts of cGMP in all HTM culture supernatants (Fig. 3). IWP-953 (0.1–10 μM) stimulation alone (in the absence of 10 μM DETA-NO) had very little effect on supernatant cGMP levels with all values below 10 nM, except for HTM141 culture supernatants (17.2 nM) at 10 μM IWP-953 (Supplementary Table S2).

Ex Vivo Mouse Eye Perfusions With IWP-953

In order to examine the impact of IWP-953 on conventional outflow cell function in an intact model, we perfused paired enucleated mouse eyes with drug (10–100 μM) or vehicle in the contralateral eye as a control. This model functionally isolates pressure-dependent conventional outflow from other physiological contributors to IOP like inflow, uveoscleral outflow, and episcleral venous pressure. Anterior chambers were cannulated and eyes were subjected to sequential pressure steps, while flow was continuously measured. Shown in Figure 4 are perfusion data from a representative experiment with paired eyes, one treated with vehicle and the other with 100 μM IWP-953. Displayed are flow traces from both eyes at four sequential pressure steps. Notice that flow at each pressure, except for the first, is greater in the drug-treated eye. Data from multiple perfusions such as this example are used to generate pressure/flow plots and calculate outflow facility.

Shown in Figures 5A through 5E are pressure/flow plots for each treatment. Linear regression analysis of the slope of pressure-flow curves estimates outflow facility (pressure-dependent outflow). Results show that increasing concentr-
tions of IWP-953 improved outflow facility, with a maximum and significant ($P = 0.002$) effect at the highest concentration (0.045 vs. 0.024 μL/min/mm Hg); approximately doubling outflow facility (89.5% increase). We also observed that the 60-μM concentration was significantly different than paired controls (0.032 vs. 0.022 μL/min/mm Hg), increasing outflow facility by 49.3%. In contrast, the two lowest concentrations were without detectable effect (0.024 vs. 0.025 and 0.026 vs. 0.022 μL/min/mm Hg). As a positive control, a cohort of eyes was treated with 100 μM DETA-NO, which significantly ($P = 0.030$) increased outflow facility by 97.5%. A side-by-side comparison of treatment effects on outflow facility are shown in panel F of Figure 5.

**DISCUSSION**

We provide evidence that IWP-953 stimulation of the sGC-cGMP pathway in primary cultures of HTM cells significantly increased cGMP production in myofibroblast-like HTM120 and HTM123 and endothelial-like HTM130 and HTM141 cultures, but the magnitude of intracellular cGMP production is less pronounced in endothelial-like HTM130 and HTM141 cells. Importantly, pharmacologic effects of IWP-953 observed in vitro translated in an ex vivo model of IOP control, eliciting a substantial increase in outflow facility. These data suggest a novel, previously unrecognized mechanism functionally linking pharmacologic effects of sGC stimulation and modulation of the sGC-cGMP pathway to therapeutic benefit in an established model of glaucoma.

Soluble guanylate cyclase stimulators act synergistically with NO to increase the activity of sGC and thus may be therapeutically useful to enhance NO signaling, particularly in conditions or diseases in which NO signaling may be impaired.26 Recent FDA approval of the sGC stimulator riociguat (Adempas; Bayer Pharma AG, Leverkusen, Germany) for treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension highlights the therapeutic potential of this class of drugs and importantly, provides clinical validation for sGC as a therapeutic target.27,28 IWP-953 is a novel sGC stimulator that elicits potent in vitro pharmacologic effects, concentration-dependently stimulating cGMP production in HEK-293 cells (EC$_{50}$: 17 nM) in the presence of DETA-NO. This stimulation is sGC-dependent as it can be inhibited by the presence of the sGC inhibitor, ODQ. Similar to findings in HEK-293 cells, in vitro exposure of primary cultures of HTM cells to IWP-953 in the presence of DETA-NO resulted in significant and concentration-dependent increases in intracellular cGMP levels. Interestingly, the magnitude of this response clearly differentiates myofibroblast-like HTM120 and HTM123 cells from endothelial-like HTM130 and HTM141 cells, with markedly higher intracellular cGMP levels detected in HTM120 and HTM123 cultures. Due to the nature of our TM cell isolation technique, all cultures are mixed. However, cultures are often dominated by endothelial or myofibroblastic cell isolates, depending upon the condition of the donor tissue and age of the donor, explaining the spectrum of responses of these four cell strains. Taken together, our functional data with primary cultures of human cells from the TM are consistent with previous reports showing select populations of cells in the TM tissue and in cell culture with contractile characteristics.17–21

Cells that occupy the beams and plates of the inner TM are endothelial-like, while cells that reside in the juxtacanalicular connective tissue (JCT) are myofibroblast-like and highly contractile.29 Stimulation with IWP-953 in the absence of DETA-NO also increased cGMP levels in all HTM cultures, but the potency of this effect was generally one to three orders of magnitude below that observed in the presence of DETA-NO, providing further evidence for strong synergy between sGC stimulators and NO and the likely importance of this synergy for the observed pharmacologic activities. These findings suggest that the highly contractile myofibroblast cell population within the TM/JCT network is a primary target of IWP-953, thereby modulating sGC-cGMP pathway downstream events by a mechanism(s) potentially involving cytoskeletal actin fiber.
assembly/disassembly. Changes in the dimensions of the trabecular outflow pathway, through IWP-953 induced alterations in cell morphology and contractile tone of these myofibroblasts could then lead to decreased outflow resistance in the inner wall region and lower IOP.

The activity of cGMP phosphodiesterases is generally recognized as the major elimination pathway controlling intracellular cGMP levels. However, findings from recent studies in different model systems have identified an important role for the ATP-binding cassette transporter multidrug resistance–associated protein-4 (MRP4) in intracellular cGMP homeostasis, including IOP by controlling the relaxation characteristics of cells in the conventional AH outflow pathway.30–32 Multidrug resistance–associated protein-4, via a

![Figure 5](image_url)

**Figure 5.** Pressure versus flow plots showing impact of escalating concentrations of IWP-953 on conventional outflow function of enucleated mouse eyes. Ex vivo perfusions were conducted using (A) 10 μM, (B) 30 μM, (C) 60 μM, and (D) 100 μM IWP-953, or vehicle as control for comparisons. Eyes were subjected to four pressure steps (4, 8, 12, and 16 mm Hg), and flow was continuously monitored. Linear regression was performed on mean flow data at each pressure step (±SD) to estimate outflow facility. As a positive control (E), 100 μM DETA-NO was perfused into a separate cohort of eyes, with contralateral eyes perfused with vehicle. A summary of outflow facility calculations at each concentration is shown in panel F as a box-and-whisker plot (*P < 0.05).
mechanism of directing the unidirectional efflux of cGMP, has been described as an overflow pump supporting the decrease of intracellular cGMP levels under conditions of strongly induced cGMP production and importantly, cGMP for potential paracrine actions.33,34 Consistent with this postulated role of MRP4, we found significantly increased levels of extracellular cGMP in culture supernatants of primary culture of HTM cells treated with IWP-953 and DETA-NO, in a concentration-dependent manner. Interestingly, clinical studies found significantly lower cGMP concentrations in AH from POAG patients, compared to cGMP levels in the AH of normal pressure glaucoma patients, but no physiological role of extracellular cGMP in the TM outflow pathway is currently known.35,36 However, extracellular cGMP following activation of the intestinal guanylate cyclase-C/cGMP pathway has recently been shown to elicit potent analgesic effects in models of visceral pain via modulation of the activity of colonic sensory afferents. Furthermore, direct inhibitory effects of extracellular cGMP on central nervous system neurons results in reduced excitability and inhibition of neurotransmitters, suggesting that studies aiming to elucidate a potential role of extracellular cGMP in the modulation of AH outflow pathways are warranted.37–41

Next we examined pressure-dependent outflow in perfused enucleated mouse eyes ex vivo. Pressure-controlled perfusion directly measures conventional outflow in the absence of confounding factors such as AH inflow, uveoscleral outflow, and episcleral venous pressure. Intracameraly perfused IWP-953 stimulated a concentration-dependent increase in outflow, and the effect of IWP-953 observed at the highest concentration (100 μM) was significant and comparable to that of DETA-NO. Notably, this potent effect on mouse outflow facility was not dependent on costimulation with an exogenous NO donor, suggesting the presence of a basal NO tone in conventional outflow tissues. Since the bulk of conventional outflow resistance is generated proximal to or at the endothelium of the Schlemm’s canal or downstream vessels and Schlemm’s canal cells produce NO, it is likely that NO released from Schlemm’s canal cells is responsible for the basal NO tone and thus, the regulation of conventional outflow.1,2 Our results with IWP-953 in mouse eyes provide further evidence supporting the concept of pharmacologic targeting of the sGC–cGMP pathway for the treatment of POAG.42–46 Moreover, direct targeting the sGC–cGMP pathway with a sGC stimulator possesses advantages over NO donor strategies. NO donors, in addition to stimulating the sGC–cGMP pathway, may also elicit nonspecific biological responses via a cGMP-independent, noncanonical pathway, through covalent posttranslation- al S-nitrosylation of target proteins.47,48

Finally, both the sGC activator BAY58-2667 and the sGC stimulator YC-1 increase conventional outflow mechanistically linked to changes in TM cell volume, mediated through activation of the sGC–cGMP–cGK1 pathway in a manner dependent on the large-conductance calcium-activated potassium channel (BKCa), a channel with dense distribution in the TM that integrates multiple signals leading to cell relaxation.6 However, both BAY58-2667 and YC-1 elicit biphasic effects on TM cell volume, characterized by sGC–cGMP dependent decreases at lower concentrations, but cGMP independent increases at higher concentrations.6 While we have not investigated the effects of IWP-953 on TM cell volume in this study, our data support a concentration-dependent effect on increased outflow facility.

To date, the only proven treatment strategy for glaucoma is to lower IOP, either by increasing outflow or decreasing the production of AH. Pharmacologic inhibitors of ROCK are a novel class of drugs currently in late-stage clinical development that selectively target the conventional outflow pathway downstream of NO–sGC–cGMP signaling.5 Mechanistically, these drugs act independent of cytosolic calcium levels via a singular mode of action, diminishing the contractile tone of conventional outflow pathway tissues and disrupting components of the actin–myosin cytoskeleton, thereby increasing outflow facility and lowering IOP.49–51 In contrast, the effects of IWP-953 relaxing the contractile tone of the TM are likely mediated through multiple mechanisms. Activation of the cGMP downstream effector cGK1 directly counteracts the effects of the Rho-ROCK pathway by phosphorylation and activation of myosin light chain phosphatase, resulting in myosin light chain dephosphorylation and relaxation of the TM contractile tone. Simultaneously, via regulation of BKCa channels, cGK1 decreases calcium influx into the cytosol, thus inactivating calcium/calmodulin-dependent myosin light chain kinase and preventing increased TM contractility.52

In summary, these studies provide compelling evidence that IWP-953 acts on sGC to enhance NO–cGMP signaling predominantly in highly contractile myofibroblast-like TM cells, an effect that translated in an established model of glaucoma, increasing outflow facility. These findings suggest sGC stimulators have the potential to emerge as a new therapeutic class of ocular hypotensive drugs selectively targeting the conventional outflow pathway.

Acknowledgments

The authors thank G. Todd Milne for critical reading and constructive comments on this manuscript and W. Michael Dismuke for assisting with the construction of Figure 4.

The project was supported by Ironwood Pharmaceuticals, EY022359, EY005722, and Research to Prevent Blindness Foundation.

Disclosure: P. Ge, Ironwood (E); I.D. Navarro, None; M.M. Kessler, Ironwood (E); S.G. Bernier, Ironwood (E); N.R. Perl, Ironwood (E); R. Sarno, Ironwood (E); J. Masferrer, Ironwood (E); G. Hannig, Ironwood (E); W.D. Stamer, Ironwood (F)

References

1. Chowdhury UR, Hann CR, Stamer WD, Fautsch MP. Aqueous humor outflow: dynamics and disease. Invest Ophtalmol Vis Sci. 2015;56:2993–3003.
2. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713.
3. Grant WM. Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol. 1965;69:783–801.
4. Johnson M. What controls aqueous humor outflow resistance? Exp Eye Res. 2006;82:545–557.
5. Challa P, Arnold JJ. Rho-kinase inhibitors offer a new approach in the treatment of glaucoma. Expert Opin Invest Drugs. 2014; 23:81–95.
6. Dismuke WM, Sharif NA, Ellis DZ. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY58-2667 involves the BKCa ion channel. Invest Ophtalmol Vis Sci. 2009;50: 5353–5359.
7. Kee C, Kaufman PL, Gabelt BT. Effect of 8-Br-cGMP on aqueous humor dynamics in monkeys. Invest Ophtalmol Vis Sci. 1994;35:119–123.
8. Ellis DZ, Dismuke WM, Chokshi BM. Characterization of soluble guanylate in NO- induced increases in aqueous humor outflow facility and in the trabecular meshwork. Invest Ophtalmol Vis Sci. 2009;50:1808–1813.
9. Kotikoski H, Alajuuma P, Moilanen E, et al. Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP. J Ocul Pharmacol Ther. 2002;18:11–23.

10. Kotikoski H, Vapaatalo H, Oksala O. Nitric oxide and cyclic GMP enhance aqueous humor outflow facility in rabbits. Curr Eye Res. 2003;28:119–123.

11. Buys ES, Ko YC, Alf C, et al. Soluble guanylate cyclase γ2-deficient mice: a novel murine model for primary open angle glaucoma. PLoS One. 2013;8:e60156.

12. Chang JYH, Stamer WD, Bertrand J, et al. The role of nitric oxide in murine conventional outflow. Am J Physiol Cell Physiol. 2015;309:C205–C214.

13. Lei Y, Zhang X, Song M, Wu J, Sun X. Aqueous humor outflow physiology in NOS3 knockout mice. Invest Ophthalmol Vis Sci. 2015;56:4891–4898.

14. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol. 2009;191:277–308.

15. Schmidt HH, Schmidt PM, Stasch JP. NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol. 2009;191:309–339.

16. Nakai T, Perl NR, Iyengar RR, et al. Discovery of IWP-051, a novel orally bioavailable soluble guanylate cyclase stimulator with sustained and dose-dependent hemodynamic effects. BMC Pharmacol Toxicol. 2015;16(suppl 1):A59.

17. Conroneo MT, Korbmacher C, Fluegel C, Stiemer B, Luettjen-Drecoll E. Wiederholt M. Electrical and morphological evidence for heterogenous populations of cultured bovine trabecular meshwork cells. Exp Eye Res. 1991;52:375–388.

18. Fluegel C, Tamme E, Luettjen-Drecoll E. Different cell populations in bovine trabecular meshwork: an ultrastructural and immunocytochemical study. Exp Eye Res. 1991;52:681–690.

19. Stamer WD, Seftor RE, Williams SK, Samaha HA, Snyder RW. Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. Curr Eye Res. 1995;14:611–617.

20. Stamer WD, Roberts BC, Howell DN, Epstein DL. Isolation, culture, and characterization of endothelial cells from Schlemm’s canal. Invest Ophthalmol Vis Sci. 1998;10:1804–1812.

21. O’Brien ET, Wang Y, Ying H, Yue BY. Differential expression of genes in cultured cells from juxtanacalicular trabecular meshwork and Schlemm’s canal. J Ocul Pharmacol Ther. 2014;30:291–299.

22. Stamer WD, Roberts BC, Epstein DL, Allingham RR. Isolation of primary open-angle glaucomatous trabecular meshwork cells from whole eye tissue. Curr Eye Res. 2000;20:347–350.

23. Lei Y, Overby DR, Boussommier-Calleja A, Stamer WD, Ethier CR. Outflow physiology of the mouse eye: pressure dependence and washout. Invest Ophthalmol Vis Sci. 2011;52:1865–1871.

24. Rogers ME, Navarro ID, Perkums KM, et al. Pigment epithelium-derived factor decreases outflow facility. Invest Ophthalmol Vis Sci. 2013;54:6655–6661.

25. Boussommier-Calleja A, Li G, Wilson A, et al. Physical factors affecting outflow facility measurements in mice. Invest Ophthalmol Vis Sci. 2015;56:8331–8339.

26. Follmann M, Griebenow N, Hahn MG, et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Annu Rev Chem. 2013;52:2–23.

27. Rubin LJ, Galic N, Grimmer F, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015;45:1303–1315.

28. Simonneau G, D’Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. 2015;45:1293–1302.

29. Dismuke WM, Liang J, Overby DR, Stamer WD. Concentration-related results of nitric oxide and endothelin-1 on human trabecular meshwork cell contractility. Exp Eye Res. 2014;120:28–35.

30. Pattabiraman PP, Pecen PE, Rao PV. MRP4-mediated regulation of intracellular cAMP and cGMP levels in trabecular meshwork cells and homeostasis of intraocular pressure. Invest Ophthalmol Vis Sci. 2013;54:1636–1649.

31. Krawutschke C, Koesling D, Russwurm M. Cyclic GMP in vascular relaxation: export is of similar importance as degradation. Arterioscler Thromb Vasc Biol. 2015;35:2011–2019.

32. Tchernychev B, Ge P, Kessler MM, et al. MRP4 modulation of the guanylate cyclase-C/cGMP pathway: effects on linaclootide-induced electrolyte secretion and cGMP efflux. J Pharmacol Exp Ther. 2015;355:1–9.

33. Ritter CA, Jedlitschky G, Meyer zu Schwabedissen H, Grube M, Koeck K, Kroemer HK. Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab Rev. 2005;37:253–278.

34. Sager G. Cyclic GMP transporters. Neurochem Int. 2004;45:865–875.

35. Galassi F, Sodi A, Ucci F, Renieri G, Pieri B, Masini E. Ocular hemodynamics and nitric oxide in normal pressure glaucoma. Acta Ophthalmol Scand Suppl. 2000;222:37–38.

36. Galassi F, Renieri G, Sodi A, Ucci F, Vannozzi L, Masini E. Nitric oxide oxides and ocular perfusion pressure in primary open angle glaucoma. Br J Ophthalmol. 2004;88:757–760.

37. Cervetto C, Maura G, Marcoli M. Inhibition of presynaptic release-facilitatory kainite autoreceptors by extracellular cyclic cGMP. J Pharmacol Exp Ther. 2010;332:210–219.

38. Linden DJ, Dawson TM, Dawson VL. An evaluation of the nitric oxide/cGMP/cGMP-dependent protein kinase cascade in the induction of cerebellar long-term depression in culture. J Neurosci. 1995;15:5098–5105.

39. Poupolopou C, Nowak LM. Extracellular 3’,5’ cyclic guanosine monophosphate inhibits kainite-activated responses in cultured mouse cerebellar neurons. J Pharmacol Exp Ther. 1998;286:99–109.

40. Castro J, Harrington AM, Hughes PA, et al. Linaclootide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine-3’,5’-monophosphate. Gastroenterology. 2013;145:1334–1346.

41. Silos-Santiago I, Hannig G, Eutamene H, et al. Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation. Pain. 2013;154:1820–1830.

42. Sumida GM, Stamer WD. S1P receptor regulation of sphingosine-1-phosphate effects on conventional outflow physiology. Am J Physiol Cell Physiol. 2011;300:C1164–C1171.

43. Millard LH, Woodward DF, Stamer WD. The role of prostaglandin EP4 receptor in the regulation of human outflow facility. Invest Ophthalmol Vis Sci. 2011;52:3506–3513.

44. Boussommier-Calleja A, Bertrand J, Woodward DF, Ethier CR, Stamer WD, Overby DR. Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes. Invest Ophthalmol Vis Sci. 2012;53:5838–5845.

45. Li G, Farsiu S, Chiu SJ, et al. Pilocarpine-induced dilatation of Schlemm’s canal and prevention of lumen collapse at elevated intraocular pressures in living mice visualized by OCT. Invest Ophthalmol Vis Sci. 2014;55:3737–3746.

46. Overby DR, Bertrand J, Schicht M, Paulsen F, Stamer WD, Luettjen-Drecoll E. The structure of the trabecular meshwork, its connections to the ciliary muscle, and the effect of pilocarpine on outflow facility in mice. Invest Ophthalmol Vis Sci. 2014;55:3727–3736.
47. Gould N, Doulias P-T, Tenopoulou M, Raju K, Ischiropoulos H. Regulation of protein function and signaling by reversible cysteine S-nitrosylation. *J Biol Chem*. 2013;288:26473–26479.

48. Hess DT, Stamler JS. Regulation by S-nitrosylation of protein post-translational modification. *J Biol Chem*. 2012;287:4411–4418.

49. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y27632. *Invest Ophthalmol Vis Sci*. 2001;42:1029–1037.

50. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated kinase inhibitor Y-27632 on intraocular pressure and outflow facility. *Invest Ophthalmol Vis Sci*. 2001;42:137–144.

51. Honjo M, Inatani M, Kido N, et al. Effects of protein kinase inhibitor, HA 1077, on intraocular pressure and outflow facility in rabbit eyes. *Arch Ophthalmol*. 2001;119:1171–1178.

52. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. *Physiol Rev*. 2006;86:1–23.